Vosevi (SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR)
Vosevi (SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Vosevi; Generic name: SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR; Drug class: Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC].
| Brand name | Vosevi |
|---|---|
| Generic name | SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR |
| Drug class | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC] |
| Manufacturer | Gilead Sciences, Inc. |
| Used for | 1 INDICATIONS AND USAGE VOSEVI is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have [see Dosage and Administration (2.2) and Clinical Studies (14) ]: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor. |
| Dosage | 2 DOSAGE AND ADMINISTRATION Testing: Prior to initiating VOSEVI, test all patients for HBV infection by measuring HBsAg and anti-HBc. ( 2.1 ) Recommended dosage: One tablet (400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir) taken orally once daily with food. ( 2.2 ) See recommended treatment regimen and duration in table below ( 2.2 ): Genotype Patients Previously Treated with an HCV Regimen Containing: VOSEVI Duration 1, 2, 3, 4, 5, or 6 An NS5A inhibitor In clinical tria |
| Warnings | WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with VOSEVI. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals (DAA) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HC |
| Active ingredient(s) | SOFOSBUVIR |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17ffc094-8ca7-45d2-80d8-fd043bc9a221 |